Publications by authors named "Manish Shroff"
Article Synopsis
- Nirsevimab is approved in the US for preventing RSV in neonates and infants, particularly during their first RSV season, based on safety data from three clinical trials involving different populations.
- In the studies, participants were given a single dose of nirsevimab or a comparator treatment, with safety data showing that most adverse events (AEs) were mild to moderate and largely unrelated to the treatment.
- The conclusion indicated that nirsevimab has a favorable safety profile for preventing RSV disease, regardless of the infants' gestational age or pre-existing conditions.
Article Synopsis
- The Phase 3 MELODY trial evaluated the effectiveness of nirsevimab in preventing RSV in children during their second RSV season.
- Results showed that there was no increase in medically attended RSV lower respiratory infections or disease severity in children who received nirsevimab compared to those who received a placebo.
- The clinical trial is registered at Clinicaltrials.gov under NCT03979313, confirming its scientific validity.
Article Synopsis
- A study on children with congenital heart disease or chronic lung disease found that 200 mg nirsevimab is as safe as palivizumab for RSV prevention.
- Nirsevimab showed effective serum levels that could help protect healthy infants from severe RSV disease.
- The results suggest that nirsevimab could also be effective for children at high risk of severe RSV during their second RSV season.
Background: Internal thoracic arteries (ITA) have been shown to offer longer graft patency. Off-pump coronary artery bypass graft surgery (CABG) through small lateral thoracotomy has been reported. The present study deals with feasibility of using bilateral ITAs (BITA) in CABG through small lateral thoracotomy facilitated by the da Vinci robotic system.
View Article and Find Full Text PDF